TABLE 3.
Multivariate analysis in the AI fit subgroup
| n | % | Univariate | Multivariate | |||
|---|---|---|---|---|---|---|
| HR (95% CI) | p value | HR (95% CI) | p value | |||
| (A) PFS | ||||||
| Age (<74/≧75) | 241/96 | 71.5/28.5 | 1.15 (0.88–1.50) | 0.296 | 1.15 (0.88–1.51) | 0.297 |
| Sex (male/female) | 111/226 | 32.9/67.1 | 1.43 (1.11–1.84) | 0.005 | 1.30 (0.93–1.83) | 0.125 |
| Stage (relapse, IIIB/IV) | 94/243 | 27.9/72.1 | 0.52 (0.39–0.68) | <0.001 | 0.53 (0.40–0.70) | <0.001 |
| PS (0,1/2) | 290/47 | 86.1/13.9 | 0.65 (0.46–0.93) | 0.017 | 0.62 (0.43–0.89) | 0.009 |
| Smoke (former, current/never) | 190/147 | 56.4/43.6 | 1.38 (1.09–1.75) | 0.009 | 1.14 (0.82–1.57) | 0.432 |
| EGFR (L858R/19 del) | 151/186 | 44.8/55.2 | 1.25 (0.98–1.59) | 0.066 | 1.18 (0.93–1.50) | 0.173 |
| TKI (first‐, second‐generation/osimertinib) | 285/52 | 84.6/15.4 | 1.13 (0.74–1.72) | 0.582 | 1.37 (0.89–2.10) | 0.155 |
| (B) OS | ||||||
| Age (<74/≧75) | 241/96 | 71.5/28.5 | 0.75 (0.56–1.00) | 0.048 | 0.72 (0.54–0.97) | 0.032 |
| Sex (male/female) | 111/226 | 32.9/67.1 | 1.54 (1.17–2.03) | 0.002 | 1.37 (0.94–2.01) | 0.102 |
| Stage (relapse, IIIB/IV) | 94/243 | 27.9/72.1 | 0.59 (0.43–0.81) | 0.001 | 0.64 (0.47–0.88) | 0.006 |
| PS (0,1/2) | 290/47 | 86.1/13.9 | 0.65 (0.46–0.93) | 0.017 | 0.62 (0.43–0.89) | 0.009 |
| Smoke (former, current/never) | 190/147 | 56.4/43.6 | 1.38 (1.09–1.75) | 0.009 | 1.14 (0.82–1.57) | 0.432 |
| EGFR (L858R/19 del) | 151/186 | 44.8/55.2 | 1.31 (1.01–1.71) | 0.044 | 1.27 (0.97–1.65) | 0.082 |
| TKI (first‐, second‐generation/osimertinib) | 285/52 | 84.6/15.4 | 1.09 (0.56–2.10) | 0.798 | 1.19 (0.62–2.30) | 0.600 |
Abbreviations: 19 del, exon 19 deletion; CI, confidence interval; EGFR, epidermal growth factor receptor; first‐, second‐generation, gefitinib, erlotinib, and afatinib; HR, hazard ratio; PFS, progression‐free survival; PS, performance status; TKI, tyrosine kinase inhibitor.
Bold values are p <0.05, which is statistically significant.